Additionally, we assessed PD-L1 expression in tumor cells (TC) and tumor-infiltrating immune cells (IC), as well as CD8+-lymphocyte infiltration by IHC and we created mathematical models to integrate all these different biomarkers into a multivariate analysis to define the best set of biomarkers for the prediction of DCB in NSCLC and melanoma patients undergoing ICI. This evidence concerns the gene CD8A and neoplasm.